The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane

Persistently hyper-phosphorylated Akt contributes to human oncogenesis and resistance to therapy. TCN-P, the active metabolite of the Akt phosphorylation inhibitor triciribine (TCN), is in clinical trials, but the mechanism by which TCN-P inhibits Akt phosphorylation is unknown. Here we show that in...

Descripción completa

Detalles Bibliográficos
Autores principales: Berndt, Norbert, Yang, Hua, Trinczek, Bernhard, Betzi, Stéphane, Zhang, Ziming, Wu, Bainan, Lawrence, Nicholas J., Pellecchia, Maurizio, Schönbrunn, Ernst, Cheng, Jin Q., Sebti, Saïd M.
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952662/
https://www.ncbi.nlm.nih.gov/pubmed/20489726
http://dx.doi.org/10.1038/cdd.2010.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952662/
https://www.ncbi.nlm.nih.gov/pubmed/20489726
http://dx.doi.org/10.1038/cdd.2010.63

Ejemplares similares